The Prevalence of Migraine in Inflammatory Bowel Disease, a Systematic Review and Meta‑Analysis

Hamide Olfati, Omid Mirmosayyeb, Ali Mahdi Hosseinabadi, Mahsa Ghajarzadeh

Abstract


Background: Patients with inflammatory bowel disease (IBD) suffer from a wide range of comorbidities such as migraine. In studies, the prevalence of migraine in cases with IBD was reported differently. The goal of this systematic review and meta‑analysis was to estimate the pooled prevalence of migraine in IBD cases. Methods: Two researchers independently and systematically searched PubMed, Scopus, EMBASE, Web of Science, and google scholar. They also searched the gray literature including references of the included studies and conference abstracts which were published up to May 2021. Cross‑sectional studies were included. Results: The literature search revealed 840 articles, and after deleting duplicates, 650 remained. For the meta‑analysis, 10 studies were included. Totally, 62,554 patients were evaluated. The pooled prevalence of migraine in patients with IBD was 19% (95% CI: 15–22%). The pooled prevalence of migraine in ulcerative colitis (UC) was 10% (95% CI: 4–15%) (I2 = 99.8%, P < 0.001). The pooled prevalence of migraine in the Crohn’s disease (CD) group was 24% (95% CI: 17–30%) (I2 = 98.8%, P < 0.001). The pooled odds of developing migraine in IBD cases was 1.51 (95% CI: 1–2.27) (I2 = 90.8%, P < 0.001). Conclusions: The result of this systematic review and meta‑analysis showed that the pooled prevalence of migraine in patients with IBD was 19% (95% CI: 15–22%).

Keywords


Inflammatory bowel disease; migraine disorders; prevalence

Full Text:

PDF

References


Watts D, Satsangi J. The genetic jigsaw of inflammatory bowel

disease. Gut 2002;50(Suppl 3):III31‑6.

Moisset X, Bommelaer G, Boube M, Ouchchane L, Goutte M,

Dapoigny M, et al. Migraine prevalence in inflammatory bowel

disease patients: A tertiary‐care centre cross‐sectional study. Eur

J Pain 2017;21:1550‑60.

Card TR, Langan SM, Chu TP. Extra‑gastrointestinal

manifestations of inflammatory bowel disease may be less

common than previously reported. Dig Dis Sci 2016;61:2619‑26.

Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A,

Rogler G. Extraintestinal manifestations of inflammatory bowel

disease. Inflamm Bowel Dis 2015;21:1982‑92.

Vavricka SR, Brun L, Ballabeni P, Pittet V, Vavricka BM,

Zeitz J, et al. Frequency and risk factors for extraintestinal

manifestations in the Swiss inflammatory bowel disease cohort.

Am J Gastroenterol 2011;106:110‑9.

Elsehety A, Bertorini TE. Neurologic and neuropsychiatric

complications of Crohn’s disease. South Med J 1997;90:606‑10.

Greenstein AJ, Janowitz HD, Sachar DB. The extra‑intestinal

complications of Crohn’s disease and ulcerative colitis: A study

of 700 patients. Medicine (Baltimore) 1976;55:401‑12.

Cheraghi SC, Daryani NE, Ghabaee M. A survey on migraine

prevalence in patients with inflammatory bowel disease‑A single

centre experience. Middle East J Dig Dis 2016;8:282‑8.

Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine

is first cause of disability in under 50s: Will health politicians

now take notice? J Headache Pain 2018;19:17.

Ford S, Finkel AG, Isaacs KL. Migraine in patients with

inflammatory bowel disorders. J Clin Gastroenterol 2009;43:499.

Dimitrova AK, Ungaro RC, Lebwohl B, Lewis SK,

Tennyson CA, Green MW, et al. Prevalence of migraine in

patients with celiac disease and inflammatory bowel disease.

Headache 2013;53:344‑55.

Modesti PA, Reboldi G, Cappuccio FP, Agyemang C,

Remuzzi G, Rapi S, et al. Panethnic differences in blood pressure

in Europe: A systematic review and meta‑analysis. PLoS One

;11:e0147601.

Peterson J, Welch V, Losos M, Tugwell PJ. The Newcastle‑Ottawa

Scale (NOS) for Assessing the Quality of Nonrandomised

Studies in Meta‑Analyses. Ottawa: Ottawa Hospital Research

Institute; 2011. p. 1‑12.

Leitão AM, Junior HL, Araújo DF, Braga LL, Souza MH,

Barbosa AM, et al. Neuropathy and primary headaches affect

different subgroups of inflammatory bowel disease patients.

Neurol Sci 2021;42:935‑42.

Bähler C, Schoepfer AM, Vavricka SR, Brüngger B, Reich O.

Chronic comorbidities associated with inflammatory bowel

disease: Prevalence and impact on healthcare costs in

Switzerland. Eur J Gastroenterol Hepatol 2017;29:916‑25.

Anadol Kelleci U, Calhan T, Sahin A, Kahraman R, Ozdil K,

Sokmen HM, et al. The Prevalence of headache in Crohn’s

disease: Single‑center experience. Gastroenterol Res Pract

;2016:6474651.

Ghersin I, Khateeb N, Katz LH, Daher S, Shamir R, Assa A.

Comorbidities in adolescents with inflammatory bowel disease:

Findings from a population‑based cohort study. Pediatr Res

;87:1256‑62.

Belkaid Y, Naik S. Compartmentalized and systemic control of

tissue immunity by commensals. Nat Immunol 2013;14:646‑53.

Vanmolkot FH, Van Bortel LM, de Hoon JN. Altered

arterial function in migraine of recent onset. Neurology

;68:1563‑70.

Sadeghniiat K, Rajabzadeh A, Ghajarzadeh M, Ghafarpour M.

Sleep quality and depression among patients with migraine. Acta

Med Iran 2013;51:784‑8.

Mirmosayyeb O, Shaygannejad V, Ghajarzadeh M. Comparison

of psychological difficulties in patients with migraine and

epilepsy using PARADISE‑24 questionnaire. J Multidiscip

Healthc 2020;13:609‑13.

Jalilian R, Ghajarzadeh M, Fateh R, Togha M, Sahraian MA,

Azimi A. Comparison of sleep quality in women with migraine

moreover, multiple sclerosis. Acta Med Iran 2014;52:690‑3.

Cavestro C, Ferrero M. Migraine in systemic autoimmune diseases.

Endocr Metab Immune Disord Drug Targets 2018;18:124‑34.

Buse DC, Reed ML, Fanning KM, Bostic R, Dodick DW,

Schwedt TJ, et al. Comorbid and co‑occurring conditions

in migraine and associated risk of increasing headache pain

intensity and headache frequency: Results of the migraine in

America symptoms and treatment (MAST) study. J Headache

Pain 2020;21:1‑16.

El‑Sonbaty HA‑E, Zarad CA, Mohamed MR, Elmaaty A,

Ahmed A. Migraine in patients with rheumatoid arthritis and its

relation to disease activity. Egypt J Neurol Psychiatr Neurosurg

;57:1‑10.

Mirmosayyeb O, Barzegar M, Nehzat N, Shaygannejad V,

Sahraian MA, Ghajarzadeh M. The prevalence of migraine in

multiple sclerosis (MS): A systematic review and meta‑analysis.

J Clin Neurosci 2020;79:33‑8.

Mathieu S, Couderc M, Pereira B, Dubost J‑J,

Malochet‑Guinamand S, Tournadre A, et al. Prevalence of

migraine and neuropathic pain in rheumatic diseases. J Clin Med

;9:1890.

O’Mahony SM, Clarke G, Borre Y, Dinan T, Cryan J. Serotonin,

tryptophan metabolism and the brain‑gut‑microbiome axis.

Behav Brain Res 2015;277:32‑48.

Hamel E, Currents H. Serotonin and migraine: Biology and

clinical implications. Cephalalgia 2007;27:1293‑300.

Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J,

Blaszyk H, et al. Molecular defects in mucosal serotonin

content and decreased serotonin reuptake transporter in

ulcerative colitis and irritable bowel syndrome. Gastroenterology

;126:1657‑64.

Sarchielli P, Floridi A, Mancini M, Rossi C, Coppola F, Baldi A,

et al. NF‑κB activity and iNOS expression in monocytes from

internal jugular blood of migraine without aura patients during

attacks. Cephalalgia 2006;26:1071‑9.

Leira R, Sobrino T, Rodríguez‐Yáñez M, Blanco M, Arias S,

Castillo J. Mmp‐9 immunoreactivity in acute migraine. Headache

;47:698‑702.

Vanmolkot F, Hoon JD. Increased C‑reactive protein in young

adult patients with migraine. Cephalalgia 2007;27:843‑6.